A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes

Recruiting

• Conditions: ASTHMA
• Interventions: Other: Non-interventional

• Registration Number: NCT05728749
• Lead Sponsor: Chiesi SAS

Brief Summary

TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (beclometasone/formoterol/glycopyrronium).

Detailed Description

TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (beclometasone/formoterol/glycopyrronium).

Trimbow is a fixed triple therapy containing a long-acting muscarinic antagonist (LAMA, glycopyrronium), a long-acting beta-adrenergic agonist (LABA, formoterol) and an inhaled corticosteroid (ICS, beclometasone).

Asthma patients often need to use multiple inhalers as part of their therapy, which require different inhalation techniques. It has been shown that the use of several inhalers of different mode of action, design and dosage requirements may have a detrimental effect on patient adherence and subsequent treatment outcomes.

In this prospective, non-interventional trial, the investigators aim to evaluate aspects of adherence to Trimbow, a single-inhaler triple therapy (SITT) as a maintenance treatment of asthma, to gather knowledge from routine care on whether appropriate step-up to SITT leads to greater adherence and better health outcomes.

Study Timeline

• Study First Submitted: 2023-02-06
• Study First Submitted QC: 2023-02-06
• Study First Posted: 2023-02-15
• Study Start: 2023-03-03
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-04
• Last Update Posted: 2023-07-06
• Primary Completion: 2024-03
• Study Completion: 2025-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Patients ≥ 18 years of age,
• Patients with confirmed leading diagnosis of asthma with or without concomitant COPD,
• Physician decision to start fixed triple therapy with ICS/LABA/LAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS,
• Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study,
• Patient must be covered by a social security scheme,
• Patient must be treated by one of the practitioners of the centre (at office or at hospital).

Exclusion Criteria

• Participation in an interventional clinical trial within 30 days prior to enrolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.
• Patients unable to understand scope of study or patients unwilling to participate in study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Asthma patients	Non-interventional	Trimbow pMDI prescribed for maintenance treatment of adult asthma as per the licensed indication.

Primary Outcome Measures

Name	Time	Method
To describe patient characteristics and therapy pathways for patients with a diagnosis of moderate to severe asthma who are treated with Trimbow in real world practice	12 months	Descriptive analysis of patient demographics.

Secondary Outcome Measures

Name	Time	Method
Analyse parameters of asthma-related airway inflammation	12 months	Change from baseline in percentage of patients with a fraction of exhaled nitric oxide (FeNO) below or above 20 ppb.
Assess adverse events associated with use of Trimbow	12 months	Assessment of the number and type of adverse events.
Analyse the incidence of asthma exacerbations	12 months	Number of exacerbations 12 months prior to baseline and during study.
Analyse use of rescue medication	12 months	Use of any rescue medication 7 days prior to baseline and during study 7 days prior to respective visit.
Analyse parameters of lung function using spirometry	12 months	Change from baseline in FEV1.
Assess asthma control (ACT)	12 months	Change from baseline in ACT scores.
Analyse parameters of small airways disease	12 months	Change from baseline in small airway function measured by pre-dose AUCAX (Area under the curve of reactance) using available oscillometry system.
Assess retention rate with Trimbow	12 months	Assess continuation of treatment with Trimbow (retention rate of Trimbow) at month 12.
Assess quality of life	12 months	Change from baseline in Mini-AQLQ scores.
Analyse use of systemic corticosteroids	12 months	Use of any systemic corticosteroids 12 months prior to baseline and during study.
Assess treatment adherence	12 months	Change from baseline in TAI scores.
Analyse parameters of persistent airflow limitation	12 months	Change from baseline in percentage of patients with persistent airflow limitation (PAL); PAL defined as post-BD FEV1 \<80% predicted and post-BD FEV1/FVC Ratio \< 0.7.
Analyse the severity of asthma exacerbations as defined by the American Thoracic Society/European Respiratory Society (ATS/ERS) classification of asthma exacerbations	12 months	Severity of exacerbations, defined according to the ATS/ERS classification of asthma exacerbations, will be analysed 12 months prior to baseline and during study.

Trial Locations

Locations (1)

ChiesiFrance; 🇫🇷 Bois-Colombes, France